Superworth

PTC Therapeutics price to sales ratio PTCT

Market value divided by revenue over the last twelve months, since 2014.

Today, Oct 23, 2026
5.0×
10-year median
5.6×
Against its 10-year history
41st
percentile: 0 is its lowest day, 100 its highest
10-year range
0.7× to 13.0×
Peer median
7.8×

PTC Therapeutics' price to sales ratio is 5.0× as of Oct 23, 2026.

That is below its ten-year median of 5.6×, close to the middle of its last ten years.

Over that time it ranged from 0.7× in May 2026 to 13.0× in Jan 2021.

The median for 10 large drugmakers of a similar size is 7.8×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.0×0.7×6.1×
20253.5×2.0×5.6×
20243.9×2.1×4.1×
20232.6×1.8×5.8×
20223.9×3.4×6.3×
20215.7×5.1×13.0×
202011.6×8.1×12.9×
201910.1×5.8×10.4×
20186.3×5.3×9.1×
20174.9×3.6×9.8×
20165.3×2.4×26.9×
201530.3×25.1×141×
2014105×12.3×112×

Against its peers

Companies in Drug Manufacturers - General nearest PTC Therapeutics' size, closest first, today.

CompanyPrice to sales ratio
PTCTPTC Therapeutics5.0×
KNSAKiniksa Pharmaceuticals International7.1×
LGNDLigand Pharmaceuticals20.8×
INDVIndivior Pharmaceuticals3.1×
AMRXAmneal Pharmaceuticals2.1×
ARQTArcutis Biotherapeutics8.5×
LQDALiquidia8.5×
OGNOrganon0.6×
ALKSAlkermes plc.4.4×
TGTXTG Therapeutics10.4×
PTGXProtagonist Therapeutics31.8×
Peer median7.8×

Where PTC Therapeutics ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on PTC Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.